: iStockAnalyst.com Symbols Feed

Spotlight On: Biotech

Sun, 09 Aug 2009 19:06:17 GMT

Spotlight On: Biotech The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen, Biogen Idec, Genetech, Genzyme, Life Technologies and Monsanto. Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this industry. Biotech products and treatments tend to be expensive and the drive to reduce costs through rationing will no doubt effect this industry. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential[More...]

Five Things to Remember in 2009

Tue, 23 Dec 2008 13:47:00 GMT

Looking back through 2008, the Healthcare sector has hit some huge hurdles. Patent concerns and expirations were worries for all major firms, the Department of Justice hit Med Tech with fines, Big Pharma made thousands of job cuts, Managed Care got demolished with enrollment cuts, and investors struggled to find much, if any safety in the whole sector. Going forward, 2009 will be quite an interesting year in the markets and the ever-so struggling economy. More M&A activity and consolidation will not only be seen within the Financials sector, but will also spread across other sectors. We have seen this ramp up quite a bit in Due to lofty predictions by some analysts regarding unforeseen buyouts of large Biotech firms by Big Pharma, heated debates on the Street will be prevalent. Some names that have been thrown out are Merck buying Gilead and Pfizer purchasing Amgen. Although those are pretty big bets, nonetheless, it will[More...]

Five Healthcare Stocks To Diversify Your Portfolio

Tue, 18 Nov 2008 14:14:00 GMT

In no way do I feel the market has bottomed out or that the credit crisis has skidded to a halt, but in the words of Warren Buffet, “Be fearful when others are greedy and be greedy when others are fearful.” What does this mean for you, an investor? Invest in equities, now! In past articles I have noted that the Healthcare sector’s mistakenly being referred to as “recessionary proof” is quite a misconception; however, as a long-term investor (minimum three years), like myself, you should be “greedy.” And what a perfect time it is to be greedy.Consumer Confidence hit an all-time low of 38 in October, it’s lowest level since inception in 1967. An intelligent investor will act now. It is time to restructure your personal portfolio, and you should look to[More...]

Generics Giant Teva Shines

Sun, 09 Nov 2008 17:48:00 GMT

With another tough day in the market following the Presidential Election, the word’s largest generic drug maker topped 3rd Quarter net profit forecasts. Teva (TEVA: 42.55, +2.0477 (+5.06%)), headquarted in Israel, develops, manufactures, and markets generic and human pharmaceuticals. They also participate in the formation of active pharmaceuticals, or APIs, in North America, Europe, Latin America, Asia, and Israel. Teva’s net profit for the quarter, excluding one-time items, was $599 million or $0.72 per diluted share, compared with $525 million, or $0.64 per share. Sales increased 20% to a record of[More...]

Teva Beats On Profits: A Biogeneric Boon In '09?

Thu, 06 Nov 2008 13:51:00 GMT

Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than doubled from 3Q07 at $710M. Teva also expects to close its acquisition of Barr Pharma (BRL) by[More...]

Weekly Mergers and Acquisitions Report (Oct 29 - Nov 4)

Tue, 04 Nov 2008 22:21:00 GMT

Barr Pharmaceuticals (BRL) - Teva Pharmaceutical (TEVA) , *Rio Tinto (RTP) - BHP Billiton (BHP), Alpha Natural Resources, Inc. (ANR) - Cleveland-Cliffs Inc (CLF), $Datascope Corp. (DSCP) - Getinge AB[More...]

A Bullish Outlook for Generic Drugs After Election

Tue, 04 Nov 2008 03:52:00 GMT

In addition to the favorable underlying trends I wrote about previously for the generic drug industry, both presidential candidates are bullish on the industry with the following excerpts taken directly from their websites: Senator Obama: Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs and[More...]

Virtual Funds: Healthcare Fund's Ranking/Performance In Q3 '08 And Overall

Sat, 01 Nov 2008 17:26:00 GMT

Among all the sectors, healthcare has held up better than most. Of course, now, with the benefit of hindsight, various pundits and talking heads are pointing out that this is the safe haven with a lot of growth potential. What's the logic here? Since this sector has lost the least, it must grow the most now? Nonsense. If anything, now is probably not the time to invest in the healthcare considering the significance of upside potential in other, very beaten-down sectors. If you're nevertheless curious about what has done relatively well so far, here I will detail the performance of the virtual mutual fund I've set up for the Healthcare sector on the Marketocracy web site. Orange line in the chart below shows how my Healthcare Fund has performed relative to the m100 (a collective Marketocracy fund that uses picks from the top 100 members), S&P 500, Dow Jones Index, and Nasdaq. [More...]

Weekly Mergers and Acquisitions Report - Oct 21 2008 9:08AM

Tue, 21 Oct 2008 12:51:00 GMT

Anheuser-Busch Cos. (BUD) - InBev, $Datascope Corp. (DSCP) - Getinge AB, Secure Computing Corporation (SCUR) - McAfee, Inc. (MFE), Barr Pharmaceuticals (BRL) - Teva Pharmaceutical (TEVA), NDS Group plc (NNDS) - News Corporation (NWS)[More...]

Barr Pharma Deal Should Close - Analyst Blog

Mon, 13 Oct 2008 20:48:00 GMT

Barr Pharmaceuticals, Inc. (BRL) is a global specialty pharmaceutical company engaged in the development, manufacture and marketing of branded and generic drugs. On July 18, 2008, Barr announced that it has entered into an agreement with Teva Pharmaceuticals (TEVA) whereby the latter will acquire Barr for $7.46 billion plus the assumption of net debt of approximately $1.5 billion. We had issued a Sell rating on Barr after the company posted disappointing first-quarter results and slashed its full-year outlook. However, we moved back to a Hold rating following the Teva takeover announcement. This offer has come at the right time for Barr -- the deal should close later this year. We[More...]

BRIEF: Teva Pharmaceutical Industries Receives Approval to Buy Barr Laboratories in Forest

Sat, 20 Dec 2008 14:08:00 GMT

Dec. 20--The parent company of Barr Laboratories in Forest has received the last approval it needs to move forward and be bought by an Israel-based drug maker.
The merger between Barr Pharmaceuticals and Teva Pharmaceutical Industries has received approval from the U.S. Federal Trade Commission, the two companies announced on Friday.
That announcement came shortly after the companies said they had received antitrust approval from the European Commission to move ahead.

[More...]

Movers: Citigroup, Google, Barr Labs, Microsoft, Merrill Lynch

Mon, 21 Jul 2008 19:46:00 GMT

Citigroup (C) posts narrower-than-expected $0.54 second quarter loss per share, vs. $1.24 EPS a year ago, on 29% revenue drop.
But says second quarter results improved substantially versus first quarter due to lower write-downs, good performance in core franchise.
Google (GOOG) posts $3.92, vs. $2.93 a year ago, second quarter GAAP EPS on 39% revenue rise.

[More...]

Warner Chilcott and Barr Announce Settlement of Femcon(R) Fe Patent Challenge

Mon, 22 Dec 2008 20:55:00 GMT

Warner Chilcott Limited today announced that its subsidiary Warner Chilcott Company, Inc. and Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. , have entered into a Settlement and License Agreement to resolve the pending patent litigation involving Warner Chilcott's oral contraceptive product, Femcon Fe.[More...]

U.S. Federal Trade Commission Clears Teva’s Acquisition of Barr

Fri, 19 Dec 2008 18:56:00 GMT

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that the U.S. Federal Trade Commission ("FTC") has accepted the proposed consent order in connection with the pending acquisition of Barr by Teva and granted early termination of the Hart Scott Rodino waiting period.[More...]

U.S. Federal Trade Commission Clears Teva's Acquisition of Barr

Fri, 19 Dec 2008 18:55:00 GMT

Closing scheduled for December 23, 2008[More...]

Teva and Barr Receive European Commission Approval For Acquisition

Fri, 19 Dec 2008 18:15:00 GMT

Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that they received approval from the European Commission to proceed with Teva's acquisition of Barr.[More...]

Teva and Barr Receive European Commission Approval for Acquisition

Fri, 19 Dec 2008 17:21:00 GMT

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that they received approval from the European Commission to proceed with Teva's acquisition of Barr.[More...]

Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA

Thu, 11 Dec 2008 13:49:00 GMT

Barr Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for review Duramed Pharmaceuticals, Inc.'s Adenovirus Types 4 and 7 Live Oral Vaccines Biologics License Application . These oral vaccines represent Barr's first in-house biologics development initiative and demonstrate the Company's ability to develop, manufacture and conduct clinical trials for biologic products. The Prescription Drug User Fee Action date for the Adenovirus BLA is July 31, 2009.[More...]

Teva Draws on $1.75 Billion Bridge Financing in Connection with Pending Barr Acquisition

Mon, 08 Dec 2008 17:11:00 GMT

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that it has completed the drawdown of its combined $1.75 billion bridge loan facilities with Bank Hapoalim B.M. and Bank Leumi USA. The proceeds of the loans will be used towards funding Teva's previously announced acquisition of Barr Pharmaceuticals, Inc. (NYSE: BRL). Teva intends to fund the remaining cash portion of the consideration by using its cash and marketable securities on hand.[More...]

FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream

Mon, 01 Dec 2008 13:01:00 GMT

- First Local Estrogen Therapy Indicated for the Treatment of Both Moderate to Severe Vaginal Dryness and Pain With Intercourse - Symptoms of Vulvar and Vaginal Atrophy Due to Menopause[More...]

Barr Confirms Patent Challenge of Amrix(R) Extended-Release Capsules, 15mg & 30mg

Wed, 26 Nov 2008 16:16:00 GMT

Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Anesta in connection with its Amrix extended-release capsules, 15mg and 30mg.[More...]

Barr Shareholders Approve Pending Teva Acquisition

Fri, 21 Nov 2008 17:55:00 GMT

Barr Pharmaceuticals, Inc. today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals Industries Ltd. .[More...]